A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers

Cancer Gene Therapy

Volumn 4, Issue 6, 1997, Pages 383-390

  Seth, Prem ^a   Katayose, Dai ^a   Li, Zhuangwu ^a   Kim, Min ^a   Wersto, Robert ^b   Craig, Caroline ^a   Shanmugam, Naga ^c   Ohri, Ekta ^a   Mudahar, Bali ^a   Rakkar, Amol N S ^a   Kodali, Padmaja ^a   Cowan, Kenneth ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NONE

Author keywords

Adenovirus; Bone marrow purging; Breast cancer; Drug resistance; Gene therapy

Indexed keywords

DNA FRAGMENT; DOXORUBICIN; MITOXANTRONE; PROTEIN P53;

ADENOVIRUS; APOPTOSIS; ARTICLE; BIOSYNTHESIS; BONE MARROW PURGING; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; CLONOGENIC ASSAY; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; METHODOLOGY; MULTIDRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; APOPTOSIS; BONE MARROW PURGING; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; DNA FRAGMENTATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; GENES, P53; HEMATOPOIETIC STEM CELLS; HUMANS; MITOXANTRONE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031263872     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Moscow JA, Schneider E, Cowan KH. Multidrug resistance. In: Pinedo HM, Longo DL, Chabner BA, eds. Cancer Chemotherapy and Biological Response Modifiers Annual 16. Amsterdam: Elsevier Science B.V.; 1996:111-132.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by multidrug transporter. Annu Rev Biochem. 1993;62:385-427.
3. Gottesman MM, Ambudkar SV, Ni B, et al. Exploiting multidrug resistance to treat cancer. Cold Spring Harb Symp Quant Biol. 1994;59:677-683.
4. Gulati SC, Lemoli RM, Igarashi T, Atzpodien J. Newer options for treating drug-resistant (MDR+) cancer cells using photoradiation therapy. Leuk Lymphoma, 1994;12: 427-433.
5. Katayose D, Gudas J, Nygeun H, Cowan KH, Seth P. Cytotoxic effects of adenovirus-mediated wild type p53 protein expression in normal and tumor mammary epithelial cells. Clin Can Res. 1995;1:889-898.
6. Katayose D, Wersto R, Cowan KH, Seth P. Effects of a recombinant adenovirus expressing WAF/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Differ. 1995; 6:1207-1212.
7. Craig C, Wersto R, Kim M, et al. A recombinant adenovirus expressing p27/Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene. 1997;14:2283-2290.
8. Li Z, Shanmugam N, Katayose D, et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 1997;4:113-117.
9. Seth P, Brinkmann U, Schwartz GN, et al. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res. 1996;56:1346-1351.
10. Seth P, FitzGerald D, Willingham M, Pastan I. Pathway of adenovirus entry into cells. In: Crowell R, Lonberg-Holm K, eds. Virus Attachment and Entry Into Cells. Washington, DC: American Society for Microbiology; 1986:191-195.
11. Gudas J, Nguyen H, Li T, et al. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis. 1996;17:1417-1427.
12. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993; 75:817-825.
13. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994;9:2261-2268.
14. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
15. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
16. Ruley HE. p53 and response to chemotherapy and radiotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: Lippincott-Raven Publishers; 1996:37-56.
17. Safran H, King T, Choy H, et al. p53 mutations do not predict responses to paclitaxel/radiation for non small cell lung carcinoma. Cancer. 1996;78:1203-1210.
18. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287-2291.
19. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg. 1996;112:1372-1376.
20. O'Shaughnessy JA, Cowan KH, Nienhuis AW, et al. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemo-therapy for metastatic breast cancer. Hum Gene Ther. 1994;5:891-911.
21. Deisseroth AB, Holmes F, Hortobagyi G, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Hum Gene Ther. 1996;7:401-416.
22. Hesdorffer C, Antman K, Bank A, Fetell M, Mears G, Begg M. Human MDR gene transfer in patients with advanced cancer. Hum Gene Ther. 1994;5:1151-1160.
23. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, ed. Gene Transfer and Expression Protocols. NJ: Humana Press; 1991:109-128.
24. Berkner, KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunolog. 1992; 158:39-66.
25. Garver RI, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT. Strategy for achieving selective killing of carcinomas. Gene Ther. 1994;1:46-50.
26. Jolly D. Viral vectors system for gene therapy. Cancer Gene Ther. 1994;1:51-64.
27. Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 1994;54:2055-2059.
28. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
29. Lee CT, Ciernik IF, Wu S, et al. Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus. Cancer Gene Ther. 1996;3:238-244.
30. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol. 1996;156:3357-3365.